Clinical trials
Soft Tissue Sarcoma clinical trials
Below are recruiting soft tissue sarcoma clinical trials, each written for real people, not researchers. We’re tracking 181 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07156565RecruitingPhase 1
Study of actinium therapy for advanced soft tissue sarcoma
This trial is testing a new type of radiation therapy for advanced soft tissue sarcoma that has not responded to other treatments. The goal is to see if this therapy can shrink tumors and help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Phoenix, ArizonaAges 18 years+ - NCT07662239Recruiting
Exercise program for young sarcoma survivors
This study tests a personalized exercise service for teenagers and young adults who have had sarcoma. It aims to help you get active and stay healthy after treatment.
Boston, MassachusettsAges 15–39 - NCT07283731RecruitingPhase 2
Testing zanzalintinib plus pembrolizumab for certain sarcomas
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
Houston, TexasAges 18 years+ - NCT06537596RecruitingPhase 1
Imaging test for soft tissue sarcoma and other tumors
This study tests an imaging agent that may help see tumors with a specific protein called PDGFR alpha. It may help doctors better understand your cancer and plan treatment.
Brisbane, QueenslandAges 18 years+ - NCT06263231RecruitingPhase 3
Study of INT230-6 injection for soft tissue sarcoma
This study tests an experimental drug, INT230-6, injected directly into tumors, compared to the usual treatments for soft tissue sarcoma. It aims to see if the injection is safe and works better for people whose cancer has not responded to earlier treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT03965234RecruitingPhase 1/Phase 2
Lung infusion for colorectal cancer that has spread to the lungs
This trial tests a procedure where chemotherapy is delivered directly into the lungs during surgery to remove or destroy lung tumors. It aims to reduce the chance of cancer returning after surgery for people with colorectal cancer that has spread to the lungs.
Buffalo, New YorkAges 18 years+ - NCT06367075RecruitingPhase 2
Cadonilimab plus adriamycin for advanced soft tissue sarcoma
This trial tests a combination of two drugs—cadonilimab (a type of immunotherapy) and adriamycin (chemotherapy)—for adults with advanced soft tissue sarcoma that hasn't been treated before. The goal is to see if this combination helps shrink tumors or slow their growth.
Wuhan, HubeiAges 18–75 - NCT07444619RecruitingPhase 1
Combination drugs for returning soft tissue sarcoma in young people
This trial tests if combining four drugs (pazopanib, trabectedin, ipilimumab, and nivolumab) can help treat soft tissue sarcomas that have come back. It is for children and young adults up to age 30.
Houston, TexasAges 1–30 - NCT06644287Recruiting
PET scan to track immunotherapy response in advanced sarcoma
This trial uses a special PET scan called 68Ga-grazytracer to see how well your soft tissue sarcoma responds to immunotherapy treatment. It may help doctors understand if the treatment is working.
Shanghai, Shanghai MunicipalityAges 6–80 - NCT05620693Recruiting
Cell therapy study for NY-ESO-1–positive soft tissue cancer
This trial tests an engineered immune cell treatment (NY-ESO-1 TCR-T) for people with advanced soft tissue sarcoma that has returned or spread after standard treatment. It aims to treat cancer cells that show a specific marker (NY-ESO-1) in the tumor.
Shenzhen, GuangdongAges 18–70 - NCT05146440RecruitingPhase 1/Phase 2
Test drug PM14 alone and with radiation for soft-tissue sarcoma
This early-phase study tests PM14 (a new cancer treatment) to see if it can shrink tumors in soft-tissue sarcoma. Some people also receive radiation, aiming to improve tumor control while keeping side effects manageable.
Zaragoza, AragonAges 18–75 - NCT04751409RecruitingPhase 2
Less versus more follow-up after sarcoma surgery
This trial compares two schedules of post-treatment check-ups to see which one better supports patient quality of life. You’d fill out surveys for up to two years to measure how you feel over time.
Houston, TexasAges 18 years+ - NCT04330456Recruiting
Radiation plus surgery for first soft tissue sarcoma
This trial studies a treatment plan for newly diagnosed soft tissue sarcoma that combines precisely targeted radiation before surgery and conformal radiation after surgery. It may help by improving tumor control while allowing the surgeon to remove the tumor safely.
Saint PetersburgAges 18–75 - NCT05301283RecruitingPhase 2
Adaptive radiation therapy before surgery for soft-tissue sarcoma
This trial tests a personalized (“adaptive”) radiation plan before surgery for high-grade soft-tissue sarcoma that can be removed. It may help shrink the tumor and improve how well surgery can treat the cancer.
Tampa, FloridaAges 18 years+ - NCT06327477RecruitingPhase 1/Phase 2
A new type of radiation for newly diagnosed retroperitoneal sarcoma
This trial tests a new way of giving radiation called proton spatially fractionated radiotherapy (P-SFRT) combined with standard radiation for people with a type of sarcoma in the back of the belly. The goal is to see if this combination can treat the tumor more effectively.
Chicago, IllinoisAges 18 years+ - NCT05839275RecruitingPhase 1/Phase 2
Radiation plus two medicines for high-risk soft tissue sarcoma
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06062927Recruiting
Genes and scans predict response to immunotherapy and targeted therapy for advanced sarcoma
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Beijing, Beijing MunicipalityAges 18–75 - NCT06981637RecruitingPhase 2
PLD vs. observation for advanced soft tissue sarcoma
This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).
Kaohsiung CityAges 18 years+ - NCT05774275RecruitingPhase 1/Phase 2
Testing combined radiation, chemotherapy, and immunotherapy for high-risk sarcoma
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05978024Recruiting
Predicting how sarcoma responds and side effects from limb radiotherapy
This study collects information to predict how soft tissue sarcoma in an arm or leg will respond to radiotherapy and what side effects may happen. It may help doctors improve planning and follow-up for people like you.
CambridgeAges 16 years+ - NCT05876715RecruitingPhase 1/Phase 2
Testing 3 immunotherapy drugs for hard-to-remove soft tissue cancer
This Phase 1/2 study tests lurbinectedin plus two immune checkpoint medicines (ipilimumab and nivolumab) for soft tissue sarcoma that is hard to remove or has spread. It aims to see how well the combination works and how safe it is, especially for people with limited treatment options.
Santa Monica, CaliforniaAges 18–90 - NCT06409013Recruiting
Dye-guided surgery for sarcoma removal
This study tests whether using a special dye during surgery helps doctors see and remove sarcoma tumors more completely. It may help improve the chances that no cancer is left behind.
Rochester, MinnesotaAges 18 years+ - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Soft Tissue Sarcoma trials by city
Studies with a site in or near these metro areas.
Soft Tissue Sarcoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for soft tissue sarcoma?
- Yes. Clin2 currently lists 181 recruiting soft tissue sarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a soft tissue sarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a soft tissue sarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.